AIkido Pharma (AIKI) Stock Price, News & Analysis

Company Overview

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.

Key Stats

• Today's Range: $4.39 to $4.66
• 50-Day Range: $3.37 to $11.62
• 52-Week Range: $3.31 to $11.48
• Volume: 207,377 shs
• Average Volume: 79,326 shs
• Market Capitalization: $25.23 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AIKI Stock Analysis - Frequently Asked Questions

How have AIKI shares performed this year?

AIkido Pharma's stock was trading at $0.9844 at the beginning of the year. Since then, AIKI stock has increased by 367.3% and is now trading at $4.60.
View the best growth stocks for 2025 here.

When did AIkido Pharma's stock split?

Shares of AIkido Pharma reverse split before market open on Tuesday, June 7th 2022. The 1-17 reverse split was announced on Tuesday, June 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split.

Does AIkido Pharma have any subsidiaries?

AIkido Pharma subsidiaries include Hoth Therapeutics.

How do I buy shares of AIkido Pharma?

Shares of AIKI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AIkido Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AIkido Pharma investors own include Atossa Therapeutics (ATOS), iBio (IBIO), Bionano Genomics (BNGO), Ocugen (OCGN), Meta Platforms (META), Cineverse (CNVS) and

Company Calendar

• Today: 4/26/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Commercial physical research
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AIKI
• CIK: 12239
• Web: www.spherix.com
• Phone: (112) 745-1374
• Fax: 703-992-9348
• Employees: 4
• Year Founded: 1967

Profitability

• EPS (Most Recent Fiscal Year): ($3.88)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,170,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -18.21%
• Return on Assets: -16.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 29.54
• Quick Ratio: 29.54

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 2,523.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $19.27 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 5,485,000
• Free Float: 5,013,000
• Market Cap: $25.23 million
• Optionable: Not Optionable
• Beta: 0.93